Abstract
It was clearly demonstrated that good local control by either radiotherapy or D2 surgery is essential to cure gastric cancer. D2 surgery can be carried out safely with a large volume of patients and can provide better survival than limited surgery. More extended surgery than D2 cannot provide better survival and causes greater morbidity; therefore, it should not be carried out as prophylactic lymphadenectomy. The effect of adjuvant treatment depends on the type of surgery. Neoadjuvant plus post-operative triplet chemotherapy, postoperative adjuvant chemoradiotherapy, and postoperative S-1 monotherapy now are the standards of care in Europe, the United States, and Japan, respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sasako M (2004) Role of surgery in multidisciplinary treatment for solid cancers. Int J Clin Oncol 9:346–351
Fielding J (1989) Gastric cancer: different diseases. Br J Surg 76:1227
Macdonald JS, Smalley SR, Benedetti J, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730
Bonenkamp JJ, Hermans J, Sasako M, et al. (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340(12):908–914
Cuschieri A, Weeden S, Fielding J, et al. (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79(9–10):1522–1530
Brennan MF (1999) Lymph-node dissection for gastric cancer. N Engl J Med 340:956–957
Sasako M, Saka M, Fukagawa T, et al. (2007) Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg 24:101–107
Wu CW, Hsiung CA, Lo SS, et al. (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7:309–315
Sasako M, Sano T, Yamamoto S, et al. (2006) Randomized phase III trial of standard D2 versus D2 + Para-aortic lymph node (PAN) dissection (D) for clinically M0 advanced gastric cancer: JCOG9501. Presented at 2006 ASCO Annual Meeting, Atlanta, GA, June 2–6, 2006 (abstract)
Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Neri B, Andreoli F, Boffi B, et al. (2001) Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow up. Br J Cancer 84:878–880
Bajetta E, Buzzoni R, Mariani L, et al. (2002) Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13:299–307
Chipponi J, Hugier M, Pezet D, et al. (2004) Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 187:440–445
Bouché O, Ychou M, Burtin P, et al. (2005) Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16:1488–1497
Nitti D, Wils J, Dos Santos JG, et al. (2006) Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 17:262–269
De Vita F, Giuliani F, Orditura M, et al. (2007) Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 18:1354–1358
Nakajima T, Nashimoto A, Kitamura M, et al. (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Lancet 354:273–277
Nashimoto A, Nakajima T, Furukawa H, et al. (2003) Randomized trial of adjuvant chemotherapy with mitimycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 21:2282–2287
Miyashiro I, Furukawa H, Sasako M, et al. (2005) No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer. Presented at the 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, January 27–29, 2005 (abstract)
Nakajima T, Kinoshita T, Nashimoto A, et al. (2007) Randomized controlled study of adjuvant uracil-tegaful versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 94:1468–1476
Sakuramoto S, Sasako M, Yamaguchi T, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820
Kim SK, Lim DH, Lee JY, et al. (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiotherapy in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol 63:1279–1285
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sasako, M. Surgery and adjuvant chemotherapy. Int J Clin Oncol 13, 193–195 (2008). https://doi.org/10.1007/s10147-008-0791-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-008-0791-1